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Background: GABAA receptor subunit composition has a profound effect on the receptor’s physiological and
pharmacological properties. The receptor β subunit is widely recognised for its importance in receptor assembly,
trafficking and post-translational modifications, but its influence on extrasynaptic GABAA receptor function is less
well understood. Here, we examine the pharmacological properties of a potentially native extrasynaptic GABAA
receptor that incorporates the β1 subunit, specifically composed of α4β1δ and α4β1 subunits.
Results: GABA activated concentration-dependent responses at α4β1δ and α4β1 receptors with EC50 values in the
nanomolar to micromolar range, respectively. The divalent cations Zn2+ and Cu2+, and the β1-selective inhibitor
salicylidine salicylhydrazide (SCS), inhibited GABA-activated currents at α4β1δ receptors. Surprisingly the α4β1
receptor demonstrated biphasic sensitivity to Zn2+ inhibition that may reflect variable subunit stoichiometries
with differing sensitivity to Zn2+. The neurosteroid tetrahydro-deoxycorticosterone (THDOC) significantly increased
GABA-initiated responses in concentrations above 30 nM for α4β1δ receptors.
Conclusions: With this study we report the first pharmacological characterisation of various GABAA receptor ligands
acting at murine α4β1δ GABAA receptors, thereby improving our understanding of the molecular pharmacology of
this receptor isoform. This study highlights some notable differences in the pharmacology of murine and human
α4β1δ receptors. We consider the likelihood that the α4β1δ receptor may play a role as an extrasynaptic GABAA
receptor in the nervous system.
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GABAA receptors are pentameric ligand-gated ion chan-
nels that mediate phasic and tonic inhibition in the cen-
tral nervous system [1]. When activated by GABA the
integral ion channel opens, rendering the receptor per-
meable to chloride ions. The co-assembly of combina-
tions of 19 different subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π
and ρ1-3) into homo- or hetero-pentameric receptors
results in multiple different GABAA receptor isoforms
with different function, pharmacology and neuronal lo-
cation [2-4]. The stoichiometry of the majority of these* Correspondence: inge_villumsen@hotmail.com
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unless otherwise stated.receptors is considered to be 2α:2β:1γ/δ, predominantly
arranged as β-α-β-α-γ/δ in an anticlockwise manner
when viewed from the extracellular space [5-7]. How-
ever, the arrangement for δ subunit-containing receptors
seems to be dependent on the experimental conditions
[6,8-12].
Receptors incorporating α1, α2 or α3 subunits most
commonly assemble with β and γ subunits, and are gen-
erally located at the synapse where they mediate phasic
inhibition; whereas α4 and α6-containing receptors as-
semble with β and δ subunits, and are found extrasynap-
tically, mediating tonic inhibition [13]. The δ subunit is
found almost exclusively in the extrasynaptic domain
and forms α4βδ or α6βδ receptors in the cortex and
cerebellum, respectively [2]. However, it has also been
suggested that δ can co-assemble with α1 subunits in
hippocampal interneurons [14,15].ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Examples of GABA-activated currents recorded from
cDNA-injected Xenopus oocytes expressing α4β1δ and α4β1
receptors. A, Representative membrane currents for α4β1δ
receptors (upper panel) and α4β1 receptors (lower panel) in
response to increasing concentrations of GABA. The oocytes were
voltage clamped at -60 mV. B, GABA concentration response curves
for α4β1δ (n = 6) and α4β1(n = 5) receptors. All data points
represent means ± SEMs.
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as the hippocampal dentate gyrus is well established, but
there is a paucity of data which characterises the potential
native expression of the α4β1δ receptor [2]. This is largely
due to the limited number of β1-subtype-selective com-
pounds available [16], and the fact that no β1 subunit
knock-out mouse has been generated. As a consequence,
most previous studies investigating α4βδ receptors have fo-
cused on those subtypes containing the β2 or β3 subunits
as these are confirmed to be native receptor combinations
[2,17,18]. However, co-regulation of the expression levels of
α4, β1 and δ subunits in, for example, the periaqueductal
grey matter throughout the female oestrous cycle has been
reported, suggesting that α4β1δ receptors may perform a
hitherto overlooked important physiological role [19]. Also,
experimental evidence for the co-expression of α4, β1 and
δ subunits at extrasynaptic sites exists for pyramidal hippo-
campal neurons [20]. Furthermore, recent studies have em-
phasized the importance of β1-containing receptors in
relation to sleep control [21] and ataxia [22], and poly-
morphic mutants of the β1 subunit are thought to be im-
portant in determining the extent of alcohol consumption
[23]. Therefore, since α4, β1 and δ subunits are co-
expressed in several brain regions [24], the possibility exists
that these subunits can co-assemble into native functional
receptors, most likely at extrasynaptic sites, raising the pro-
spect that such a receptor subtype may be important for
neuronal physiology.
Few studies have investigated the properties of either
human [25-27] or murine [23,28] recombinant α4β1δ
receptors, and none of these have fully addressed the
characterisation of classic GABAA receptor ligands. In
these studies, interesting pharmacological differences
between murine and human α4β1δ receptors are
manifest: human receptors expressed in Xenopus oo-
cytes [25] are constitutively active and display a GABA
EC50 in the mid-nanomolar range whereas the rat/
mouse receptor expressed in oocytes or HEK293 cells
display low-micromolar sensitivity towards activation
by GABA [23,28]. To address this apparent species-
dependent pharmacology and to address the effects of
commonly used GABA receptor ligands, we report the
pharmacological profiles for several GABAA receptor
ligands at recombinant murine α4β1 and α4β1δ recep-
tors expressed in Xenopus laevis oocytes.
Results
GABA concentration response relationships for α4β1 and
α4β1δ receptors
GABA concentration response curves were generated
for α4β1 and α4β1δ receptors to evaluate GABA po-
tency at these receptors. Oocytes were challenged with
increasing concentrations of GABA (Figure 1A). De-
pending upon expression levels, maximal currents toGABA ranged from 100 to 3000 nA for cells expressing
α4β1 receptors and from 300 to 3000 nA for cells ex-
pressing α4β1δ receptors. The holding currents were
between 0 and -40 nA and the receptors were not con-
stitutively active. The GABA EC50 values were 0.89 μM
for α4β1δ receptors and 2.7 μM for α4β1 receptors
(Figure 1B, Table 1). GABA concentration-response
data were fitted as monophasic curves, with Hill coeffi-
cients of 1.1 and 0.87 for α4β1δ and α4β1 receptors, re-
spectively (Table 1).
Table 1 Pharmacological profiles of GABAA ligands at α4β1 and α4β1δ receptors
EC50 (μM) (pEC50 ± SEM) IC50 (μM) (pIC50 ± SEM) nH (± SEM) N
GABA
α4β1δ 0.89 (6.05 ± 0.05) 1.1 ± 0.11 6
α4β1 2.7 (5.56 ± 0.05) 0.87 ± 0.079 5
Zn2+
α4β1δ 3.3 (5.48 ± 0.03) −0.75 ± 0.041 6
α4β1a IC50A 6
0.00013 (9.87 ± 0.22) ND
IC50B
0.056 (7.25 ± 0.13) -1.1 ± 0.13
Cu2+
α4β1δ 0.82 (6.09 ± 0.04) −1.2 ± 0.13 12
SCS
α4β1δ 0.0042 (8.37 ± 0.25) 4
Potencies for GABA, Zn2+, Cu2+ and SCS at α4β1 and α4β1δ receptors are listed. For Zn2+ and Cu2+, inhibition was measured at the GABA EC75. For SCS, inhibition
was measured at the GABA EC20. ND, not determined.
a Data fit a two-site model (IC50A & IC50B) better than a one-site model as determined by an
F-test (p < 0.0001).
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Zn2+ has been shown to be a useful pharmacological tool
to distinguish αβ receptors from αβδ/γ receptors in re-
combinant expression systems, as δ/γ subunit-containing
GABAA receptors are less sensitive to inhibition by Zn
2+
compared to their αβ counterparts [29,30]. The increased
potency at αβ receptors is attributed to the incorporation
of a third β subunit that contains an important histidine
residue for coordinating Zn2+ ions at the top of channel
lining M2 region [30,31].
We evaluated Zn2+-inhibition of the GABA response for
both α4β1 and α4β1δ receptor isoforms to investigate
whether Zn2+ can distinguish between these receptor sub-
types. Oocytes were pre-incubated for 1 min with various
concentrations of Zn2+ followed by co-application of Zn2+
and GABA at an EC75 (3 μM for α4β1δ and 8 μM for
α4β1). As expected, Zn2+ exhibited a higher potency at
α4β1 than α4β1δ receptors. For α4β1δ receptors, Zn2+
inhibited the GABA response with an IC50 of 3.3 μM
(Figure 2A,B, Table 1). By contrast, for α4β1 receptors,
biphasic inhibitory behaviour was observed with a high
potency component (IC50A = 0.13 nM) accounting for
~25% of the total inhibition, and a more dominant lower
potency component (IC50B = 56 nM) accounting for the
remaining (~75%) inhibition (Figure 2A,B, Table 1).
Cu2+ is another well-established inhibitor of GABA cur-
rents at γ subunit-containing GABAA receptors [32], but
its inhibitory profile at δ subunit-containing receptors has
only recently been explored [33]. This revealed that Cu2+
was far more potent as an inhibitor of steady-state GABA
responses at α6β3δ receptors (IC50 = 65 nM) compared to
α1β2γ2 receptors (IC50 = 85 μM) expressed in human em-
bryonic kidney 293 (HEK293) cells [33]. To furtherinvestigate the inhibitory selectivity of Cu2+ at α4β1δ recep-
tors, we co-applied increasing concentrations of Cu2+ with
GABA (EC75: 3 μM) for 70 s, and measured the steady-
state responses, reproducing the experimental conditions
used by McGee et al. [33] to determine the IC50 values.
This response was taken as the fraction of the peak re-
sponse of a previously-applied GABA concentration, and
normalized to the steady-state response of GABA EC75 in
the absence Cu2+ (Figure 2C). An almost complete inhib-
ition of the α4β1δ GABA-activated response was observed
with increasing concentrations of Cu2+ (IC50 = 0.82 μM)
(Figure 2D, Table 1).
Inhibition by the β1 subunit-selective blocker SCS
The salicylic acid derivative, SCS, is one of only a few com-
pounds known to selectively target β1 subunit-containing
GABAA receptors over β2- and β3-containing receptors
[34]. SCS is reported to inhibit GABA-activated responses of
α2β1γ2, α2β1γ1 and α2β1γ1θ receptors, but the pharmaco-
logical profile of SCS at α4 or δ-containing receptors, has
not been addressed. To examine the interaction of SCS with
α4β1δ receptors, we evaluated the inhibition of the GABA
EC20 response following pre-application of the antagonist. In
this instance, a low EC20 concentration was chosen to enable
a direct comparison between our study and that obtained
previously [34]. SCS inhibited the GABA response with an
IC50 of 4.2 nM, but did not cause complete inhibition of the
GABA current, attaining a steady-state level of inhibition at
67.2 ± 3.2% of control (Figure 2E, Table 1).
Neurosteroid potentiation at α4β1δ receptors
Neurosteroids are potent modulators at most, if not all,
GABAA receptor isoforms [35]. Some studies report
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Figure 2 Pharmacological modulation of GABA responses at α4β1δ receptors by various inhibitors and the neurosteroid, THDOC. A,
Representative membrane currents showing inhibition of GABA (EC75) by 1 μM Zn
2+ at α4β1 (upper) and α4β1δ (lower) receptors. B, Zn2+
concentration-inhibition relationships for α4β1 (n = 6) and α4β1δ (n = 6) receptors. C, Representative currents showing the degree of desensitization
when activated by EC75 GABA in the absence (upper) and presence (lower) of 1 μM Cu2+. D, Cu2+ concentration-inhibition relationship for GABA EC75
desensitized responses at α4β1δ receptors by increasing concentrations of Cu2+ (n = 12). E, SCS concentration-inhibition relationship for GABA EC20
peak responses at α4β1δ receptors by increasing concentrations of SCS (n = 4). F, Response of α4β1δ receptors to increasing concentrations of THDOC
co-applied with an EC7 GABA concentration. The responses were normalised to a preceding application of GABA EC7 in the absence of THDOC (n = 9).
All data shown are means ± SEMs.
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subunit-containing receptors compared to their γ
subunit-containing counterparts [17,36,37]. Accordingly, we
evaluated the sensitivity of α4β1δ receptors to neurosteroid-
induced potentiation. Increasing concentrations of THDOC
were co-applied with an approximately EC7 GABA con-
centration. A significant increase in the GABA peak-
response was recorded with THDOC concentrations of
30 and 100 nM (P < 0.05, one-way analysis of variance
(ANOVA) with Dunnett’s post test, Figure 2F).
Discussion
In this study we investigated the pharmacological pro-
files of several GABAA receptor ligands at murine α4β1δ
receptors. The GABA potency of 0.89 μM (EC50) at
α4β1δ receptors determined in this study is similar to
that previously reported for the rat receptor (2.02 μM)
expressed in Xenopus oocytes [28], and the mouse/ratreceptor (1.99 μM) expressed in HEK293 cells [23].
However, a much higher GABA potency (EC50 of 24
nM) has been reported for the human α4β1δ receptor
expressed in Xenopus oocytes [25]. The GABA potency
for human α4β1 (0.72 μM) is reported to be somewhat
lower [25] than the murine combination studied here.
Furthermore, constitutive activity in the absence of
GABA was reported for the human recombinant α4β1δ
receptor [25], but this was not evident in our studies
with the murine equivalent. From these observations it
is possible that differences in constitutive activity may
explain the considerable differences in GABA potency
reported between species observed by others and in this
study. However, several other factors may also influence
the observed potency shift, such as differences in relative
subunit expression levels which may significantly impact
on the final receptor stoichiometry. In particular, δ-
containing receptors are prone to such variations in
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iations in the amount of RNA injected into Xenopus oo-
cytes apparently yield different receptor populations
[38]; likewise, concatemeric receptors also demonstrate
that alternative assemblies of functional δ-containing re-
ceptors are possible [12,39]; and from reports that both
high and low affinity conformations of the related α4β3δ
receptor apparently exist [25,40].
In this study we report the first characterisation of spe-
cific GABA antagonists at α4β1δ receptors. The approxi-
mately 60-fold potency shift in the IC50 values for Zn
2+
from low micromolar to mid nanomolar, when comparing
α4β1δ and α4β1, is consistent with prior observations
made for α4β3δ and α4β3 receptors [29]. Our determin-
ation of monophasic Zn2+ potency suggests it is highly un-
likely that there is any contamination with binary α4β1
receptors in our α4β1δ-expressing oocytes. Also, the in-
ability of Zn2+ to inhibit the response below the holding
current baseline corroborates the absence of any constitu-
tive activity caused by homomeric β1 receptors [41].
It has previously been suggested that the stoichiometry
of binary GABAA receptors containing only α and β sub-
units is dependent on the type of α and β subunit
present, with a 3α:2β stoichiometry predominating for
α1β2 receptors, but a 2α:3β stoichiometry preferred for
α4β2 receptors [11]. The biphasic inhibitory behaviour
of Zn2+ in our study would suggest the presence of a
mixed GABAA receptor population, perhaps with both
3α:2β and 2α:3β stoichiometries expressed in the oocyte.
This conclusion is rationalized by the fact that an add-
itional β subunit will contribute another H267 residue,
known to be critical for Zn2+ inhibition [31], which may
underpin the higher sensitivity component to Zn2+ in
the biphasic inhibition curves.
This study also evaluated the pharmacology of add-
itional compounds at α4β1δ known to interact with
GABAA receptors. We have established that the pharma-
cological profile of the β1-selective inhibitor SCS, at
α4β1δ receptors, is in agreement with the values re-
ported for α2β1γ2 receptors when expressed in Xenopus
oocytes (IC50 = 4.36 nM and maximum inhibition of
~33% [34], suggesting that α4 and δ subunits do not
strongly influence the molecular interaction with SCS.
Our data evaluating the inhibition of desensitized
GABA responses by Cu2+ suggest that the maximal
inhibition of Cu2+ is greater at α4β1δ (98% inhibition at
10 μM: expressed in oocytes) than at α6β3δ receptors
(expressed in HEK293) where the maximal inhibition of
the steady-state response was reported to be ~ 68% [33].
Although this difference may conceivably be due to the
different expression systems, it is equally likely that it re-
flects some subunit-selectivity (α4 > α6) for Cu2+.
As hypothesized, THDOC concentrations at 30 nM
and 100 nM were able to potentiate low (EC7) GABAconcentrations, suggesting that α4β1δ receptors are
likely to be modulated by physiologically relevant con-
centrations of neurosteroids, as akin to many other
GABAA receptor subtypes [35]. This is unsurprising
given that the highly conserved neurosteroid binding
site for potentiating GABA responses is contained
within the receptor α subunit.
Conclusions
In summary, we have extended the pharmacological
profile of the α4β1δ receptor, a subtype that has been
studied surprisingly little compared to its β2- and β3-
containing counterparts, despite its presence in many
significant brain areas. We report a high GABA potency
(EC50 of 0.89 μM), a weaker sensitivity to Zn
2+ com-
pared to α4β1 receptors, and a high sensitivity to SCS
and THDOC.
The observed discrepancy in potency compared to the
human ortholog highlights the need for caution when
making comparisons of pharmacological parameters
across species for this particular GABA receptor sub-
type. For example, in addition to the different GABA po-
tencies, there are notable differences in constitutive
activity for this receptor isoform. Whether these differ-
ences translate into the native behaviour of this receptor
remains to be determined. Finally, the different expres-
sion pattern of the β1 subunit compared to β2 and β3
subunits [24] suggests that β1-containing subtypes may
offer novel therapeutic targets and opportunities, and
emphasizes a greater need for subtype-selective ligands
and/or genetically modified mice to better understand
the native function and pharmacology of this GABAA
receptor isoform. Indeed recent findings suggest a clinic-
ally relevant role for β1-containing extrasynaptic GABAA
receptors in the nucleus accumbens mediating addictive
behaviours related to excessive alcohol intake [23].
Methods
Mouse α4 and β1 and rat δ cDNA were subcloned into
a pRK5 expression vector using methods previously de-
scribed [42]. γ-Aminobutyric acid (GABA), CuCl2 and
tetrahydro-deoxycorticosterone (THDOC) were pur-
chased from Sigma (Dorset, UK), ZnCl2 from BDP Bio-
chemical (Poole, UK) and salicylidine salicylhydrazide
(SCS) from Tocris (Bristol, UK).
Expression of GABA subunits
Oocytes from Xenopus laevis toads were prepared as de-
scribed [43]. Briefly, ovaries were removed using proce-
dures approved by the UK Animals (Scientific Procedures)
Act 1986 and local (UCL) ethics committee. To obtain
free oocytes, ovarian lobes were cut into pieces and incu-
bated in OR2 (85 mM NaCl, 5 mM HEPES, 1 mM MgCl2,
pH adjusted to 7.6 with KOH) supplemented with 2-
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Danehill, UK) for 3-4 hrs. Oocytes were washed several
times in OR2 and subsequently in Barth’s solution
(88 mM NaCl, 1 mM KCl, 0.33 mM Ca(NO3)2, 0.41 mM
CaCl2, 0.82 mM MgSO4, 2.4 mM NaHCO3, 10 mM
HEPES, pH adjusted to 7.6 with NaOH) to isolate cells
and remove follicular membranes. After preparation, the
oocytes were injected with 27 or 55 nL of 30 ng/μL cDNA
in a ratio of 1:1 (α4β1) or 1:1:5 (α4β1δ). Oocytes were sub-
sequently maintained at 18°C in Barth’s solution supple-
mented with gentamycin (Invitrogen, Paisley, UK).
Electrophysiological recordings
Recordings were performed at room temperature 2-4
days (α4β1) or 3-6 days (α4β1δ) post injection using
two-electrode voltage-clamp (Axoclamp 2B amplifier,
Digidata 1322A interface and pClamp 8 (Molecular
Devices, Wokingham, UK)). Electrodes were filled with
3 M KCl and had resistances of 0.5 to 3 MΩ. The oocytes
were clamped at a holding potential of -60 mV and were
perfused with buffer (100 mM NaCl, 2 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, 5 mM HEPES, pH adjusted to 7.4
with NaOH) throughout the recordings. All currents
were adjusted when necessary for voltage drop using
equation 1:
I ¼ Imeasured⋅ Vh−Vrevð ÞVh−Vrevð Þ þ ΔV ð1Þ
Where Imeasured is the observed current, Vh is the hold-
ing potential (mV), Vrev is the Cl
− reversal potential for
oocytes (usually ~ -30 mV), and ΔV is the change in the
holding potential (mV) due to loss of clamp during at the
peak of large GABA-evoked currents. Drugs were applied
using a fast application system coupled to a small bath vol-
ume (~1 ml), enabling drug onset times of ~ 10 ms.
Generation of concentration response curves
Agonist concentration response curves were generated
by measuring peak responses normalized to a standard
concentration of GABA applied between each or every
second application (typically an EC10-20 concentration).
To pool data from different oocytes, the data were fitted
and normalized to the calculated peak of the curve using
GraphPad Prism (version 6.0) according to equation 2;
I
Imax
¼ 1
1þ EC50GABA½ 
 n ð2Þ
where I and Imax are the GABA activated current and
maximal GABA current, respectively, and the EC50 is
the GABA concentration inducing a half-maximal re-
sponse and n is the Hill slope.Zn2+ and SCS inhibition curves were generated by
pre-application (for 60 s) of the inhibitor followed by
co-applications of the inhibitor and GABA. For each co-
application, the peak-response was measured. For Cu2+-in-
hibition curves, Cu2+ and GABA were co-applied and the
steady-state response after 70 s was measured and normal-
ized to a preceding GABA-application. All monophasic
inhibition-curves were fitted to a modified version of equa-
tion 2. The biphasic Zn2+-inhibition curve was fitted to
equation 3:
IN
== IN ¼ 1 ‐i BnH= BnH þ IC50AnHð Þð Þ‐jBnH= BnH þ IC50BnHð Þð Þ½ 
ð3Þ
where IN
/ and IN represent the normalised GABA-induced
current in the presence and absence of Zn2+ at a concen-
tration (B) respectively. (IC50)A/B define the concentrations
of Zn2+ producing 50% inhibition of the GABA-induced
current and i and j represent weighting factors for the
components A and B, where i + j = 1.
Potentiation by the neurosteroid THDOC was mea-
sured by co-application of GABA (EC7) and THDOC
until a peak response was attained. Normalized re-
sponses were pooled and plotted as mean ± SEM from
at least four different oocytes taken from at least two
different Xenopus toads. For statistical evaluation, a
repeated measures ANOVA with Dunnett’s post test
was used. The significance level was set at *P < 0.05,
**P < 0.01, ***P < 0.001. For inhibition curves, an F-test
was performed to determine whether the data was ei-
ther monophasic or biphasic.
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